Heparin Market Size, Share & Trends Analysis Report By Type (Low Molecular Weight Heparin, Unfractionated Heparin), By Route Of Administration, By Application, By End-use, By Source, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global heparin market size was valued at USD 7.42 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 2.5% from 2023 to 2030. The increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism is anticipated to drive the market. According to the CDC in 2022, each year around 900,000 people could be affected in the United States with venous thromboembolism which may result in the death of 10% - 30% of people within one month of diagnosis.

The outbreak of COVID-19 has boosted the market significantly in 2020 and 2021. As per JAMA Journal in 2021, abnormal blood clots are common in COVID-19 patients owing to clot–promoting autoantibodies which lead to deep vein thrombosis and pulmonary embolisms, which creates an opportunity for heparin. As per an article published in the Journal of the American Heart Association (JAHA) in 2021, anticoagulation therapy of low-molecular-weight heparin given in the early stages of disease could better prevent COVID‐19–associated coagulopathy and endotheliopathy that lead to a better prognosis in a patient. All the above factors are expected to contribute to market growth.

High demand for anticoagulants is anticipated to boost the overall market. Furthermore, rising health care expenditure and initiatives undertaken by government bodies are some of the key factors anticipated to drive the market growth. The increasing prevalence of chronic diseases such as cardiovascular disorders, deep vein thrombosis, pulmonary embolism, and renal diseases is considered to be one of the major factors driving the overall market.

Lack of exercise, excess smoking and drinking, unhealthy food habits, and changing lifestyles are some major factors that increase the incidence of non-communicable diseases such as coronary artery disease (CAD), hypertension, and diabetes. According to the Korea Biomedical Review, the prevalence of diabetes over 30 years stood at 13.8% in 2020. Diabetic patients have a high probability of blood coagulation which leads to heart disease and kidney complications. The use of heparin for the treatment of such conditions is projected to drive market growth.

The U.S. is experiencing a shortage of heparin in 2022 attributable to a high demand in the region. For instance, in mid-July 2022, Baxter, BBraun, Fresenius Kabi, and Pfizer are experiencing a shortage attributable to high demand and delays in manufacturing. The high demand is a result of escalated hospitalization rates in the nation owing to SARS-CoV-2.

Type Insights

The Low Molecular Weight Heparin (LMWH) segment held the highest market share of 63.7% in 2022 owing to the reliable anticoagulant effect when compared to other forms of heparin such as unfractionated heparin. The use of LMWH in the treatment of COVID-19 patients is expected to further accelerate the demand for the product. Based on an article published on Springer in 2021, the use of prophylactic doses of heparin in COVID-19 patients reduces mortality by 70% in patients with a moderate or mild form of the disease. This is expected to boost the usage of the molecule in patients.

The Ultra-Low Molecular Weight Heparin (ULMWH) segment is expected to witness the fastest growth of 2.8% over the forecast period owing to the commercialization of novel products with enhanced pharmacological effects. The better activity of ULMWH and controllability, along with low bleeding incidence is facilitating the fastest growth rate of ULMWH products.

Application Insights

The coronary artery disease segment dominated the market and accounted for the largest revenue share of 23.42% in 2022 owing to the increasing prevalence of heart-related disorders. The lack of physical activity, high blood pressure, and excess smoking are major factors contributing to the increased incidence of coronary artery disease. The increasing number of hospital stay days post-surgery and bedridden patients with restricted movements creates an opportunity for heparin as they are at high risk of blood clot development.

The venous thromboembolism segment is expected to demonstrate the fastest growth of 3.3% over the forecast period. The rising prevalence of pulmonary embolism can be attributed to the rapidly growing geriatric population and medical comorbidities. Moreover, the growing obese population globally is another factor contributing to the increasing prevalence of these diseases. Obese people are sixfold more likely to develop deep vein thrombosis.

End-use Insights

The outpatient segment dominated the market and accounted for the largest revenue share of 61.11% in 2022. Outpatients have an advantage over others due to the reduction in hospital expenses such as hospital admission costs and other hospitality-related costs. Low cost, increased availability of services, and patient convenience is key factors responsible for the large share of this segment.

The inpatient segment is expected to grow at a steady CAGR of 1.4% over the forecast period due to the improved quality of wound healing equipment and quicker recovery time in the patient. The presence of effective insurance and reimbursement policies increases the footfall of hospitals thereby expected to boost the inpatient service segment.

Source Insights

The porcine segment dominated the market and held the largest revenue share of 90.02% in 2022. The segment is expected to maintain its dominance over the forecast period due to its wide usage in the production of heparin, especially low molecular weight heparins such as enoxaparin. However, Jewish and Muslim people refrain from using porcine-derived products because of their religious beliefs, restraining the adoption of heparin.

The bovine segment is also expected to witness significant growth of 28.7% during the forecast period due to the shortage of porcine heparin due to the limited availability of intestinal mucosa and negative social beliefs about porcine heparin are major factors that boost the growth of this segment. However, the less efficacy of bovine over porcine heparin is expected to diminish the segment growth.

Route Of Administration Insights

The subcutaneous segment dominated the market and accounted for the largest revenue share of 65.12% in 2022 owing to low hospitalization-associated costs, rising demand for home care treatment, and the advantages such as ease in administration are anticipated to propel the market growth. The higher compliance rate of patients for subcutaneous heparin acts as an advantage for the segment.

The intravenous route of administration segment is expected to grow at a steady rate of 1.5% over the forecast period. Heparin, especially unfractionated heparin, is administered via the intravenous route. It offers rapid entry into the bloodstream and acts swiftly to prevent blood clots. Drug concentration control in the blood is also easier with the intravenous mode of administration.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 38.97% in 2022. This is due to the rising cardiovascular disorders and injuries. In addition, increasing healthcare expenditure levels, and growing patient awareness in this region are the factors that can be attributed to the region’s high share. According to CDC in 2022, 659,000 people in the United States die from heart disease each year which is 1 in every 4 deaths and was marked as one of the major causes of death in the country.

In the Asia Pacific, the market is projected to witness the fastest growth rate of 3.9% over the forecast period. The rising geriatric population, large population with chronic disease, and growing economies are some of the primary factors driving the growth. Asia Pacific is also the largest supplier of crude heparin and its API. This gives an advantage to local firms, such as Pharmax Lifesciences. Local companies are producing cost-effective generic medicines of patent-expired drugs.

Key Companies & Market Share Insights

Key players are adopting strategies such as new product development, merger and acquisition, and partnership to increase their market share. For instance, in January 2022, Optimvia and Ginkgo Bioworks announced a partnership to enhance biosynthetic heparin manufacturing capacity. Some of the prominent players in the heparin market include:

• Pfizer Inc.

• LEO Pharma A/S

• Dr. Reddy’s Laboratories Ltd.

• GlaxoSmithKline plc

• Sanofi

• Aspen Holdings

• Fresenius SE & Co. KGaA

• B. Braun Medical, Inc.

• Sandoz (Novartis AG)

Heparin Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global heparin market report based on type, route of administration, application, end-use, source, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Low Molecular Weight Heparin

  • Ultra-low Molecular Weight Heparin

  • Unfractionated Heparin

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Intravenous

  • Subcutaneous

• Application Outlook (Revenue, USD Million, 2018 - 2030

  • Venous Thromboembolism

  • Atrial Fibrillation

  • Renal Impairment

  • Coronary Artery Disease

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Outpatient

  • Inpatient

• Source Outlook (Revenue, USD Million, 2018 - 2030)

  • Porcine

  • Bovine

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE